Molecular Biology Reports

, Volume 38, Issue 6, pp 4205–4210 | Cite as

Program death 1 (PD1) haplotyping in patients with breast carcinoma

  • Mohammad Reza Haghshenas
  • Sirous Naeimi
  • Abdolrasoul Talei
  • Abbas Ghaderi
  • Nasrollah Erfani


Located on chromosome 2q37.3, the programmed death 1 (PD1) gene encodes for PD-1 (also known as CD279), a negative co-stimulator in the immune system. PD-1 renders potent inhibitory effects on T and B lymphocytes as well as monocyte responses. Expression of PD-1 ligands by tumor cells has been reported to contribute in immune system evasion. We aimed, in current study, to investigate the association of two single nucleotide polymorphisms in PD1 gene, +7146 G to A (PD-1.3) and +7785 C to T (PD-1.5 or +872), with susceptibility and/or progression of breast carcinoma. Four hundred forty-three women with breast cancer and 328 age-sex match healthy donors were recruited in present study. Genotyping was performed using Nested polymerase chain reaction-restriction fragment length polymorphisms. Arlequin software package was used to check for the Hardy–Weinberg equilibration and to determine the haplotypes. Results revealed no significant differences in the frequencies of genotypes and alleles at PD-1.3 (P = 0.252 and 0.279 for genotypes and alleles, respectively) and PD-1.5 positions (P = 0.522 and 0.278 for genotypes and alleles, respectively). Four haplotypes were observed among populations with no differences in the frequency between patients and controls. Our results also revealed no association between PD1 genotypes and tumor stage, tumor size, tumor grade, lymph node involvement, vascular invasion, distant metastasis, and Nottingham prognostic index. Present data do not confirm association of PD-1.3 (+7146) G/A and PD-1.5 (+7785 or +872) C/T genetic markers with susceptibility of Iranians to breast cancer.


Program death-1 (PD-1) Breast cancer Immune suppression Haplotype 



This work was financially supported by a grant from Shiraz Institute for Cancer Research (Grant no: ICR-87-500).


  1. 1.
    Ishida Y et al (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11(11):3887–3895PubMedGoogle Scholar
  2. 2.
    Agata Y et al (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8(5):765–772PubMedCrossRefGoogle Scholar
  3. 3.
    Freeman GJ et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027–1034PubMedCrossRefGoogle Scholar
  4. 4.
    Latchman Y et al (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2(3):261–268PubMedCrossRefGoogle Scholar
  5. 5.
    Carter L et al (2002) PD-1: PD-L inhibitory pathway affects both CD4 (+) and CD8 (+) T cells and is overcome by IL-2. Eur J Immunol 32(3):634–643PubMedCrossRefGoogle Scholar
  6. 6.
    Mazanet MM, Hughes CC (2002) B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 169(7):3581–3588PubMedGoogle Scholar
  7. 7.
    Yamazaki T et al (2002) Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 169(10):5538–5545PubMedGoogle Scholar
  8. 8.
    Selenko-Gebauer N et al (2003) B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol 170(7):3637–3644PubMedGoogle Scholar
  9. 9.
    Ghebeh H et al (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8(3):190–198PubMedCrossRefGoogle Scholar
  10. 10.
    Karim R et al (2009) Tumor-expressed B7-H1 and B7-DC in relation to PD-1 + T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 15(20):6341–6347PubMedCrossRefGoogle Scholar
  11. 11.
    Liu SM et al (2008) Expression and significance of B7-H1 and its receptor PD-1 in human gastric carcinoma. Zhonghua Zhong Liu Za Zhi 30(3):192–195PubMedGoogle Scholar
  12. 12.
    Ohigashi Y et al (2005) Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11(8):2947–2953PubMedCrossRefGoogle Scholar
  13. 13.
    Cao P et al. (2008) Expression and significance of PD-L1 in laryngocarcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 22 (24):1115–6, 1122Google Scholar
  14. 14.
    Ghebeh H et al (2008) FOXP3+ Tregs and B7-H1+ /PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer 8:57PubMedCrossRefGoogle Scholar
  15. 15.
    Thompson RH et al (2007) PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 13(6):1757–1761PubMedCrossRefGoogle Scholar
  16. 16.
    Wang W et al (2009) PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4 + CD25 (Hi) regulatory T cells. Int Immunol 21(9):1065–1077PubMedCrossRefGoogle Scholar
  17. 17.
    Prokunina L et al (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32(4):666–669PubMedCrossRefGoogle Scholar
  18. 18.
    Kroner A et al (2005) A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol 58(1):50–57PubMedCrossRefGoogle Scholar
  19. 19.
    Bertsias GK et al (2009) Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum 60(1):207–218PubMedCrossRefGoogle Scholar
  20. 20.
    Lin SC et al (2004) Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum 50(3):770–775PubMedCrossRefGoogle Scholar
  21. 21.
    Galea MH et al (1992) The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 22(3):207–219PubMedCrossRefGoogle Scholar
  22. 22.
    Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215PubMedCrossRefGoogle Scholar
  23. 23.
    Excoffier L, Laval G, Schneider S (2005) Arlequin: an integrated software package for population genetics data analysis. Evol Bioinform Online 1:47–50PubMedGoogle Scholar
  24. 24.
    Mu CY et al (2010) High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. doi: 10.1007/s12032-010-9515-2
  25. 25.
    Hino R et al (2010) Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116(7):1757–1766PubMedCrossRefGoogle Scholar
  26. 26.
    Iwai Y et al (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99(19):12293–12297PubMedCrossRefGoogle Scholar
  27. 27.
    Brown JA et al (2003) Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170(3):1257–1266PubMedGoogle Scholar
  28. 28.
    Prokunina L et al (2004) The systemic lupus erythematosus-associated PDCD1 polymorphism PD1.3A in lupus nephritis. Arthritis Rheum 50(1):327–328PubMedCrossRefGoogle Scholar
  29. 29.
    Prokunina L et al (2004) Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum 50(6):1770–1773PubMedCrossRefGoogle Scholar
  30. 30.
    Johansson M et al (2005) Association of a PDCD1 polymorphism with renal manifestations in systemic lupus erythematosus. Arthritis Rheum 52(6):1665–1669PubMedCrossRefGoogle Scholar
  31. 31.
    Liu JL et al (2009) Association between the PD1.3A/G polymorphism of the PDCD1 gene and systemic lupus erythematosus in European populations: a meta-analysis. J Eur Acad Dermatol Venereol 23(4):425–432PubMedCrossRefGoogle Scholar
  32. 32.
    Nielsen C et al (2003) Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 62(6):492–497PubMedCrossRefGoogle Scholar
  33. 33.
    Meng Q et al (2009) PDCD1 genes may protect against extraocular manifestations in Chinese Han patients with Vogt-Koyanagi-Harada syndrome. Mol Vis 15:386–392PubMedGoogle Scholar
  34. 34.
    Wang SC et al (2006) Programmed death-1 gene polymorphisms in patients with systemic lupus erythematosus in Taiwan. J Clin Immunol 26(6):506–511PubMedCrossRefGoogle Scholar
  35. 35.
    Lee SH et al (2006) Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. Arthritis Res Ther 8(6):R163PubMedCrossRefGoogle Scholar
  36. 36.
    Liu X et al (2009) Programmed cell death 1 gene polymorphisms is associated with ankylosing spondylitis in Chinese Han population. Rheumatol Int. doi: 10.1007/s00296-009-1264-1
  37. 37.
    Kong EK et al (2005) A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum 52(4):1058–1062PubMedCrossRefGoogle Scholar
  38. 38.
    Asad S et al (2007) No evidence of association of the PDCD1 gene with Type 1 diabetes. Diabet Med 24(12):1473–1477PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Mohammad Reza Haghshenas
    • 1
  • Sirous Naeimi
    • 1
  • Abdolrasoul Talei
    • 2
  • Abbas Ghaderi
    • 1
    • 3
  • Nasrollah Erfani
    • 1
  1. 1.Cancer Immunology Research Group, Shiraz Institute for Cancer ResearchShiraz University of Medical SciencesShirazIran
  2. 2.Department of SurgeryShiraz University of Medical SciencesShirazIran
  3. 3.Department of ImmunologyShiraz University of Medical SciencesShirazIran

Personalised recommendations